 AUSTIN, Texas, March 24, 2021 PRNewswire -- Natera, Inc. NASDAQ: NTRA, a pioneer and global leader in cell-free DNA testing, today announced that the US Food and Drug Administration FDA has granted two Breakthrough Device Designations BDDs covering new intended uses of the Signatera molecular residual disease MRD test. These new designations will support the development of Signatera through Phase III clinical trials as a companion diagnostic to two different cancer therapies. 